Brief: ABVC BioPharma Provides Vitargus Update Of Phase II Vitargus Study Protocol Received Thai FDA Approval
17/11/2022 13:41
Nov 17 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES VITARGUS® UPDATE - PHASE II
VITARGUS®
STUDY PROTOCOL RECEIVED THAI FDA APPROVAL
Source text for Eikon: ID:nGNXX1ZrP
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner